LifeVantage reported a fourth quarter in which revenue declined 9.8% year-over-year to $48.9 million, with currency-adjusted revenue down roughly 8%. Despite the top-line softness, the company delivered a resilient profitability profile, with adjusted EBITDA of $4.8 million (9.8% of revenue), flat versus the prior year, and gross margin held at 79.5%. The balance sheet remains robust (cash of $16.9 million and no debt), and capital allocation included approximately $1.8 million spent on stock repurchases in the quarter and $0.5 million in quarterly dividends, reflecting a disciplined approach to shareholder value. Management emphasized ongoing transformation initiatives (LV360), improvements in consultant engagement, and product pipeline progress as key catalysts for a stepped-up revenue trajectory in FY2025.
Management underscored the geographic mix as a meaningful driver of near-term performance, noting Americas revenue declined modestly while Asia-Pacific/Europe faced steeper declines partly due to FX headwinds. Notably, revenue per consultant rose by more than 2% year-over-year in the quarter, signaling improved productivity within the direct-distributor model amid compensation-plan enhancements. The company highlighted several strategic levers intended to lift growth and margins in 2025, including the GLP-1 weight-management system launching around October 2024, continued expansion of Liquid Collagen, and optimization of the Rewards Circle program (now offering consultant subscription benefits). Management explicitly framed FY2025 guidance as a modest improvement year-over-year with revenue in the $200â$210 million range, adjusted EBITDA of $18â$21 million, and adjusted EPS of $0.70â$0.80, signaling an ambition to return to low-double-digit EBITDA margins as the top-line stabilizes and operating efficiencies accrue.